{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:01:04Z","timestamp":1790352064137,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rosacea is a chronic skin disorder characterized by facial erythema, telangiectasias, papules and pustules. Guidelines recommend subantimicrobial doses of drugs such as doxycycline 40\u2005mg. In patients with persistent symptoms, evaluating the efficacy and safety of subantimicrobial doses of minocycline may expand treatment options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate minocycline hydrochloride 40\u2005mg extended-release capsules (formerly known as and hereafter referred to as DFD-29) as a low-dose tetracycline alternative to treat rosacea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our analysis included data from three randomized controlled trials sourced from the PubMed, Embase and Cochrane databases to compare Investigator Global Assessment treatment success (IGA-TS) scores, reduction in inflammatory lesion counts, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients using DFD-29 vs. modified-release doxycycline. Statistical analyses were conducted using RStudio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In a pooled analysis of 643 patients, DFD-29 significantly increased the likelihood of achieving a successful IGA-TS score compared with doxycycline [odds ratio (OR) 2.51, 95% confidence interval (CI) 1.80\u20133.49; P &amp;lt; 0.001;\u00a0I2 = 0%]. The DFD-29 40\u2005mg group had significantly greater reductions in IGA-TS scores compared with the DFD-29 20\u2005mg group (P = 0.02). The DFD-29 40\u2005mg group also exhibited a significantly greater reduction in inflammatory lesion counts than the doxycycline group (mean difference \u20134.56, 95% CI \u20136.18 to \u20132.93; P &amp;lt; 0.001), whereas the DFD-29 20\u2005mg group showed no significant reduction. There were no significant differences in TEAEs across groups (OR 0.96, 95% CI 0.55\u20131.66; P = 0.87; I2 = 0%), with just one SAE (atrial fibrillation) reported with DFD-29.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our meta-analysis showed that DFD-29 at 40\u2005mg daily is a superior, well-tolerated alternative to modified-release doxycycline for moderate-to-severe rosacea.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag118","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:44:08Z","timestamp":1772801048000},"page":"1803-1811","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of oral minocycline hydrochloride 40\u2005mg extended-release capsules (DFD-29) versus doxycycline in rosacea: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7918-0107","authenticated-orcid":false,"given":"Laura","family":"Ghanem","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences, Lebanese University , Beirut ,","place":["Lebanon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8998-4519","authenticated-orcid":false,"given":"Cristina Sicorschi","family":"Gutu","sequence":"additional","affiliation":[{"name":"Medgate AG , Allschwil ,","place":["Switzerland"]},{"name":"University Clinic for Psychiatry and Psychotherapy, Paracelsus Medical University , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1481-5166","authenticated-orcid":false,"given":"Daniela Luc\u00eda","family":"Mendoza-Mill\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1948-3029","authenticated-orcid":false,"given":"Carlos Alberto","family":"Monteiro Leit\u00e3o Neto","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Pavia , Pavia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-9305","authenticated-orcid":false,"given":"Martin","family":"Cevallos-Cueva","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Central del Ecuador , Quito ,","place":["Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2496-6119","authenticated-orcid":false,"given":"Devanie","family":"Martani","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universitas Tarumanagara , Jakarta ,","place":["Indonesia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4419-3998","authenticated-orcid":false,"given":"Victor Barreiros","family":"Pungirum","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Buenos Aires , Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9417-3451","authenticated-orcid":false,"given":"Camila Almeida","family":"Sardinha","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, Faculty of Minas (FAMINAS-BH) , Belo Horizonte ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-6457","authenticated-orcid":false,"given":"Peter","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Department of Dermatology, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026092511025087800_llag118-B1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40257-021-00595-7","article-title":"Rosacea: new concepts in classification and treatment","volume":"22","author":"van Zuuren","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2026092511025087800_llag118-B2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/12034754241229365","article-title":"Rosacea: pathogenesis and therapeutic correlates","volume":"28","author":"Geng","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"2026092511025087800_llag118-B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.annder.2021.11.001","article-title":"Rosacea: treatment targets based on new physiopathology data","volume":"149","author":"Cribier","year":"2022","journal-title":"Ann Dermatol Venereol"},{"key":"2026092511025087800_llag118-B4","first-page":"14","article-title":"Nonantibiotic properties of tetracyclines in rosacea and their clinical implications","volume":"14","author":"Del Rosso","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"2026092511025087800_llag118-B5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/12034754241253195","article-title":"Efficacy of treatments in reducing inflammatory lesion count in rosacea: a systematic review","volume":"28","author":"Geng","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"2026092511025087800_llag118-B6","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/bjd.15155","article-title":"DOMINO, doxycycline 40\u2005mg vs. minocycline 100\u2005mg in the treatment of rosacea: a randomized, single-blinded, noninferiority trial, comparing efficacy and safety","volume":"176","author":"van der Linden","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026092511025087800_llag118-B7","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.jaad.2020.01.077","article-title":"Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee","volume":"82","author":"Thiboutot","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026092511025087800_llag118-B8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/bjd.20485","article-title":"British Association of Dermatologists guidelines for the management of people with rosacea 2021","volume":"185","author":"Hampton","year":"2021","journal-title":"Br J Dermatol"},{"key":"2026092511025087800_llag118-B9","author":"US Food and Drug Administration"},{"key":"2026092511025087800_llag118-B10","author":"Singh"},{"key":"2026092511025087800_llag118-B11","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026092511025087800_llag118-B12","author":"Cochrane"},{"key":"2026092511025087800_llag118-B13","first-page":"16","article-title":"Minocycline extended-release comparison with doxycycline for the treatment of rosacea: a randomized, head-to-head, clinical trial","volume":"14","author":"Tsianakas","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"2026092511025087800_llag118-B14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamadermatol.2024.6542","article-title":"Efficacy, safety, and tolerability of oral DFD-29, a low-dose formulation of minocycline, in rosacea: two phase 3 randomized clinical trials","volume":"161","author":"Bhatia","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026092511025087800_llag118-B15","author":"Cochrane"},{"key":"2026092511025087800_llag118-B16","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026092511025087800_llag118-B17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2010.10.004","article-title":"Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action","volume":"63","author":"Griffin","year":"2011","journal-title":"Pharmacol Res"},{"key":"2026092511025087800_llag118-B18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/10454411910020030201","article-title":"Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs","volume":"2","author":"Golub","year":"1991","journal-title":"Crit Rev Oral Biol Med"},{"key":"2026092511025087800_llag118-B19","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/archderm.1984.01650460048018","article-title":"Neutrophil chemotaxis in patients with acne receiving oral tetracycline therapy","volume":"120","author":"Esterly","year":"1984","journal-title":"Arch Dermatol"},{"key":"2026092511025087800_llag118-B20","first-page":"131","article-title":"The influence of divalent cations and doxycycline on iodoacetamide-inhibitable leukocyte adherence","volume":"74","author":"Gabler","year":"1991","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"2026092511025087800_llag118-B21","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/AAC.01540-08","article-title":"Tetracyclines modulate protease-activated receptor 2-mediated proinflammatory reactions in epidermal keratinocytes","volume":"53","author":"Ishikawa","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092511025087800_llag118-B22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/0006-2952(92)90381-R","article-title":"Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline","volume":"44","author":"Pruzanski","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"2026092511025087800_llag118-B23","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.neuint.2006.10.008","article-title":"Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration","volume":"50","author":"Yao","year":"2007","journal-title":"Neurochem Int"},{"key":"2026092511025087800_llag118-B24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4049\/jimmunol.176.1.567","article-title":"Doxycycline modulates nitric oxide production in murine lung epithelial cells","volume":"176","author":"Hoyt","year":"2006","journal-title":"J Immunol"},{"key":"2026092511025087800_llag118-B25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00002018-199818060-00004","article-title":"Minocycline-induced pigmentation","volume":"18","author":"Eisen","year":"1998","journal-title":"Drug Saf"},{"key":"2026092511025087800_llag118-B26","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2133.1996.tb06972.x","article-title":"Safety of long-term high-dose minocycline in the treatment of acne","volume":"134","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"2026092511025087800_llag118-B27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00002018-200023040-00006","article-title":"Liver damage associated with minocycline use in acne","volume":"23","author":"Lawrenson","year":"2000","journal-title":"Drug Saf"},{"key":"2026092511025087800_llag118-B28","first-page":"1873","article-title":"Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity","volume":"25","author":"Boudreaux","year":"1993","journal-title":"Transplant Proc"},{"key":"2026092511025087800_llag118-B29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/MEG.0b013e3282f493c5","article-title":"Minocycline hepatitis","volume":"20","author":"Ford","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026092511025087800_llag118-B30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/archdermatol.2008.521","article-title":"Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae","volume":"145","author":"Brown","year":"2009","journal-title":"Arch Dermatol"},{"key":"2026092511025087800_llag118-B31","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0049-0172(99)80004-3","article-title":"Minocycline-induced autoimmune syndromes: an overview","volume":"28","author":"Elkayam","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"2026092511025087800_llag118-B32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1128\/AAC.11.4.712","article-title":"Side effects of minocycline: a double-blind study","volume":"11","author":"Fanning","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"2026092511025087800_llag118-B33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-017-0339-0","article-title":"A phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the treatment of facial papulopustular rosacea","volume":"19","author":"Mrowietz","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2026092511025087800_llag118-B34","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-024-02003-w","article-title":"Microencapsulated benzoyl peroxide for rosacea in context: a review of the current treatment landscape","volume":"84","author":"Desai","year":"2024","journal-title":"Drugs"},{"key":"2026092511025087800_llag118-B35","first-page":"E53","article-title":"Safety and pharmacokinetics of FMX103 (1.5% minocycline topical foam) in subjects with moderate-to-severe papulopustular rosacea under maximum-use treatment conditions","volume":"14","author":"Jones","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"2026092511025087800_llag118-B36","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1086\/598510","article-title":"Doxycycline, not minocycline, induces its own resistance in multidrug-resistant, community-associated methicillin-resistant Staphylococcus aureus clone USA300","volume":"48","author":"Schwartz","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026092511025087800_llag118-B37","doi-asserted-by":"crossref","first-page":"ofv178","DOI":"10.1093\/ofid\/ofv178","article-title":"Minocycline as a substitute for doxycycline in targeted scenarios: a systematic review","volume":"2","author":"Carris","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2026092511025087800_llag118-B38","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-resistant A. baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2026092511025087800_llag118-B39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.36849\/JDD.9245","article-title":"Impact of low-dose oral minocycline (DFD-29) on skin, gastrointestinal, and vaginal microflora in healthy adults","volume":"24","author":"Gallo","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"2026092511025087800_llag118-B40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1902\/jop.2008.070375","article-title":"Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease","volume":"79","author":"Preshaw","year":"2008","journal-title":"J Periodontol"},{"key":"2026092511025087800_llag118-B41","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1067\/S0190-9622(03)01154-X","article-title":"A review of the use of combination therapies for the treatment of acne vulgaris","volume":"49","author":"Leyden","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"2026092511025087800_llag118-B42","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000017852","article-title":"Comedonal diffusion of minocycline in acne","volume":"196","author":"Chosidow","year":"1998","journal-title":"Dermatology"},{"key":"2026092511025087800_llag118-B43","author":"Journey Medical Corporation"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag118\/67281647\/llag118.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1803\/67281647\/llag118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/10\/1803\/67281647\/llag118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:14Z","timestamp":1790348594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/10\/1803\/8512394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,3,9]]},"published-print":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llag118","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,3,9]]}}}